Miami Cancer Institute Research

CONGRESS | #EHA2025 | PRESENTATION Firas El Chaer @FirasElChaer @MiamiCancerInst presented findings from a phase I/II study evaluating nuvisertib monotherapy in patients with relapsed/refractory #myelofibrosis (N = 77). Nuvisertib was well tolerated with no DLTs, with activity…

CONGRESS | #EHA2025 | PRESENTATION @GuentherKoehne @MiamiCancerInst shares preliminary results from the phase I/II VBP101 trial (NCT04849910) of a CD33-deleted allograft (trem-cel), followed by gemtuzumab ozogamicin (GO) maintenance in high-risk patients with CD33+ AML or MDS…

Dr. Murugesan Manoharan, @MiamiCancerInst's chief of urologic oncology surgery, highlighted evidence-based advances in prostate cancer surgery at the Caribbean College of Surgeons 23rd Annual Scientific Conference. 🌎💡

💡@RohanGarjeMD breaks down the latest systemic therapy recommendations for metastatic castration-resistant prostate cancer (mCRPC). Insightful takeaways for clinicians navigating evolving standards of care. 📖 Read via @physicianswkly: physiciansweekly.com/asco-updates-m… #ProstateCancer…

June is Cancer Survivors Month, a time to honor strength, resilience, and life beyond treatment. At Baptist Health Cancer Care, our Survivorship Program supports every step of the journey forward. 💚 baptisthealth.net/baptist-health…

💡@DrReshmaMahtani discusses pivotal #ASCO25 presentations that may shape #breastcancer standard of care cancernetwork.com/view/pivotal-p… via @CancerNetwrk #bcsm

From brainstorming sessions in the clinic to the @ASCO stage—what a journey it’s been! Watching my mentees present at #ASCO25 was a proud and emotional moment. Keep chasing bold ideas @waraonc23 @Deebacca @supriyadocc @BHCancerCare @MiamiCancerInst @RoswellHemOnc @UBIMResidency

We’re honored to celebrate Zouina Sarfraz, MBBS (@ZouinaS), recipient of a 2025 @ConquerCancerFd Merit Award for her rigorous evaluation of SRN risk in HER2+ breast cancer brain mets. Her findings reveal a consistent increase in SRN with concurrent ADC + RT—key data for future…

#ASCO25 GAIN Trial: Neoadjuvant #Gemcitabine/cisplatin nearly doubled median OS to 27.8 months vs 14.6 months with adjuvant therapy in resectable #BiliaryTractCancer. R0 resection rates: 62.5% vs. 33.3%. bit.ly/3FIkPhf #BTC @FCI_health @Sarbaji85064063 @MiamiCancerInst

In this "Beat the Clock" segment, @BrainTumorDoc of @MiamiCancerInst, goes #OntheClock ⏱️ with Dr Chandler Park of @mednewsweek to discuss the key data he is most excited about at this year's @ASCO Annual Meeting/ #ASCO25 Check back on hubs.li/Q03q4HSM0 for more.

📍Live from #ASCO25: Our team is energized and ready for today’s powerful plenary sessions—driving forward the breakthroughs that will redefine cancer care. 🍍💡

We’re proud to see @MiamiCancerInst researchers paving the way for more inclusive databases and equitable access to precision oncology. #ASCO25 Well done! 🍍👏

Congratulations to Dr. Sarbajit Mukherjee (@Sarbaji85064063), our new Chief of GI Medical Oncology, for presenting an oral abstract on neoadjuvant strategies in biliary tract cancer. 🍍👏 We look forward to advancing these approaches in future clinical trials. #ASCO25

💡 Dr. Arelis Martir-Negron presents new research on the prevalence and diversity of BRCA1/2 pathogenic variants in South Florida’s Hispanic population. 📊 5.2% carried a BRCA1/2 P/LP variant—most in BRCA2 (68.2%)—including unique variants in patients of Cuban, Nicaraguan &…

Dr. Fatma Akkoc Mustafayev shares national data on cancer trends and survival among adolescent and young adult (AYA) patients, highlighting the need for earlier detection and age-adapted screening strategies to address this growing challenge. #ASCO25 #AYAOncology

•Day 1 Recap• Attended ‘Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies’— an insightful CME session with big strides expected ahead! 🧬🧠 #ASCO2025 @BrainTumorDoc @AzzaSarfraz @nihanakkoc

Kudos to Dr. Manmeet Ahluwalia @BrainTumorDoc for presenting research on the multi-center trial LIMITLESS, a pivotal study using microbubble-enhanced transcranial ultrasound to treat NSCLC brain metastases. This novel approach may redefine noninvasive drug delivery in…

Dr. Zouina Sarfraz shares a meta-analysis on machine learning models for glioma classification. 🧠 ML models showed strong diagnostic performance (sensitivity: 83%, specificity: 78%), but high heterogeneity limits clinical use. #ASCO25 #AIinMedicine #Glioma #NeuroOnc

💡 Dr. Rupesh Kotecha @Rrkotecha shares key findings on ADORATION, a phase I/II study combining azeliragon with SRS in patients with brain metastases. Could this novel approach enhance therapeutic response? #ASCO25

We’re live at #ASCO25 and ready for the poster presentations! Our researchers are presenting pivotal poster data on glioblastoma, breast cancer, brain metastases, and more!